The administration and suitability of intracavernous PGE-1 in men with neuro pathic erectile dysfunction is reported herein. Twenty-seven men with neuro pathic erectile dysfunction (SCI, 14; multiple sclerosis, 7; discogenic disease, 6) were evaluated and treated with intracavernous PGE-l. An average of 3.2 office sessions were required to learn adequate self-injection technique and determine optimal dosage requirements. Initial dosage for SCI men was 2.5 {tg and increased in 2.5 {tg increments to a mean maintenance dose of 6.2 {tg. Quarterly monitoring up to 28 months demonstrated satisfactory erectile rigidity and duration of erection in all patients electing to pursue home administration of PGE-l. During this interval, over 40% of patients dropped out of the treatment program. No priapism or changes in serum chemistries, CBC, or platelets were observed during this period. Corporal fibrosis although not palpable, was detected subclinically by penile ultrasound in two men. This study confirms the safety and efficacy of self-administered intracavernous PGE-1 for neuropathic impotence. However, because of a significant rate of voluntary cessation, patients should be counseled regarding the full range of therapeutic alternatives to intracavernous therapy.
Introduction
During the past decade intracavernous therapy has been investigated and widely utilized as an alternative to conventional treatment methods (penile prosthesis and vacuum erection devices). Vasoactive agents such as papaverine, phentolamine and prostaglandin E1 (PGE-l) used either as single agents or in combination have been the drugs of choice. Prostaglandin E' -l has received increasing attention because papa verine has been associated with such compli cations as corporal fibrosis, priapism and hepatic dysfunction. While intracavernous therapy can address erectile dysfunction of virtually any cause, it demonstrates the highest success rates in patients with a neurological cause.l Studies reporting the utility of intracavernous therapy among men with spinal cord injury and other neurological sources focus primarily on the intracavernous agents of papaverine mono therapy or in combination with phentol amine. 2 By contrast relatively little informa tion has been accumulated reporting the clinical experience with prostaglandin E-l in the setting of neuropathic erectile dysfunc tion. This study reports our experience with intracavernous prostaglandin E-l as a monotherapeutic agent for the treatment of neuropathic erectile dysfunction.
Patients and methods
Initial evaluation, including medical and sexual histories, physical examination, and penile brachial systolic index, was per formed in patients with neuropathic erectile dysfunction. Serum chemistries, testoster one and prolactin were routinely measured. When indicated nerve conduction studies, and nocturnal penile tumescence and duplex Doppler evaluation were carried out. In 41 men with neuropathic impotence diagnostic intracavernous POE-l injection was per formed. Of these 27 expressed a preference for continued treatment by self admin istered home therapy. The etiologic cate gories of neurological disease included spinal cord injury, 14; multiple sclerosis, 7; and disc disease, 6. In these groups the mean duration of erectile dysfunction was 8, 9, 7 years, respectively. Initial dose titration began at 2.5 f.1g of POE-I. Office-based titration doses and home maintenance doses were monitored during quarterly follow up visits up to 28 months. Subjects were in structed on the proper technique of self injection using a 27 gauge needle. Dose escalation determined by the erectile response achieved during the office dose titration phase, was performed by dose increments of 2.5 f.1g.
Over the 18 month follow up interval quarterly complete blood count (CBq, measurement of serum chemistry and penile ultrasound were performed to study out come with special reference to local and systemic complication, and assessment of erectile response.
Results
While all groups presented for treatment with a similar duration of disease, SCI men were relatively younger (Table I) . Mean maintenance doses were 6.2 f.1g, 6.8 f.1g, and 8.2 f.1g for men with SCI, multiple sclerosis and disc disease, respectively. Of the 27 patients enrolled in self administer intra cavernous therapy, 12 patients discontinued therapy when followed up to 28 months. Within each category the rate of voluntary cessation was 43%, 43% and 50% for groups of SCI, multiple sclerosis and disc disease, respectively. There were multiple reasons for discontinuation, including loss of partner, loss of interest, urinary diver sion, adrenal tumor, financial, and sub stance abuse (Table II) 4 Conversely, men with lower motor neuron injuries may achieve erections with visual sensory stimu lation via intact thoracolumbar outflow.s This psychogenic erection, however, has been described as poorly sustained and nonrigid6 limiting the possibility of adequate intromission.
Multiple sclerosis presents with a multi tude of symptoms frequently including male sexual dysfunction reported in 47-62% of patients.7 Erectile dysfunction is this setting results from abnormal or absent saltatory nerve conduction. Plaque formation charac terized by loss of oligodentrocytes and proliferation of fibrous astrocytes may occur at multiple levels in the central nervous system. These aberrations in nerve conduc tion velocity within the autonomic nervous
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system are likely to be the mechanism responsible for the symptoms of erectile dysfunction in multiple sclerosis. 8 Disc protrusion and herniation have been the cause of sacral and cauda equina com pression and variable degrees of associated erectile dysfunction.9 In addition ejaculat ory, voiding and bowel dysfunction may be observedlO if sacral outflow is affected.
Nocturnal penile tumescence studies have demonstrated the presence of nocturnal erections in patients with discogenic disease. This interesting finding suggests that neuro pathic impotence is a variable phenomenon with variable degrees on intensity. The presence of nocturnal erections in the set ting of lower motor neuron dysfunction may be explained by the intact residual cortico spinal outflow that produces nocturnal erec tions.
Prostaglandin E1 (PGE-1) has been shown to effectively relax corporal smooth muscle in in vitro studies.ll This property forms the basis for its clinical application in diagnostic protocols and therapeutic regimens for erectile dysfunction. Clinical studies of intracavernous PGE-1 have estab lished a far lower incidence of priapism, hepatic dysfunction and local fibrotic changes compared to conventional intra cavernous agents (papaverine/phentol amine).1 2
The present study demonstrates that intracavernous therapy with prostaglandin E1 is an effective therapeutic modality for the short term rehabilitation of patients with neuropathic erectile dysfunction. The con sistent and complete response of such pa tients allows for prompt rehabilitation of erectile dysfunction with minimal systemic and local adverse events. The categories of neurological disease studied herein repre sent suitable clinical settings for intracavern ous therapy. These men are generally younger than patients with vascular etiology for erectile dysfunction and therefore have less age-related vascular disease. Providing intracorporal vasoactive agents by direct intracavernous injection bypasses the neuro pathic requirements for erection to yield a satisfactory erectile response. Adequate penile rigidity can be achieved at relatively lower doses than cohorts with vascular etiology. However, because of the relatively high voluntary cessation rate noted with intracavernous therapy, long term thera peutic measures should be considered in patients with neuropathic erectile dys function.
Thus far, complications such as infection and fibrotic plaques have not been reported with PGE-l. In comparative clinical reports, PGE-l had a superior outcome compared to papaverine/phentolamine and was associ ated with a substantially lower incidence of priapism. 1 3 The incidence of priapism in men with neuropathic erectile dysfunction ranges from 10% to 25% . 2 . 14 References Paraplegia 32 (1994) [661] [662] [663] [664] Owing to the relatively functional integ rity of penile hemodynamics in these men, the complication of priapism and prolonged erection must be monitored carefully in this group. Our study demonstrates the absence of this complication in our patients with neuropathic erectile dysfunction both in the office-based dose titration phase, as well as in the home-based maintenance dosing interval.
We attribute our favorable finding to the agent itself as PGE-l has been noted in our experience and in a variety of studies to have the advantage of minimal complica tions of priapism.
